MedTrace Logo

Osteoporosis Treatment in Post-menopausal Women

NCT03006003 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2019-01-14

No results posted yet for this study

Summary

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Conditions

  • Depressive Syndrome

Interventions

DRUG

Raloxifene

Raloxifene tratment more than 4 weeks

DRUG

Alendronate

Alendronic acid 70mg with Colecalciferol 70mcg

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006003 on ClinicalTrials.gov